HC Wainwright Issues Negative Forecast for JBIO Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO) – Equities research analysts at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for shares of Jade Biosciences in a report released on Monday, June 1st. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.64) per share for the quarter, down from their prior forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.43) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.65) EPS and Q4 2027 earnings at ($0.66) EPS.

JBIO has been the topic of a number of other reports. Lifesci Capital upgraded Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. Stifel Nicolaus set a $40.00 price objective on Jade Biosciences in a research note on Friday, March 6th. Jefferies Financial Group restated a “buy” rating on shares of Jade Biosciences in a research note on Monday. William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research note on Monday, March 9th. Finally, Zacks Research raised Jade Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Jade Biosciences Stock Performance

Shares of Jade Biosciences stock opened at $17.75 on Wednesday. Jade Biosciences has a 52-week low of $6.57 and a 52-week high of $28.00. The stock’s 50-day simple moving average is $20.56 and its 200 day simple moving average is $16.50. The stock has a market capitalization of $876.14 million, a P/E ratio of -8.79 and a beta of 1.44.

Jade Biosciences (NASDAQ:JBIO) last released its earnings results on Thursday, May 7th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Jade Biosciences by 2.9% during the first quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock worth $542,000 after purchasing an additional 1,086 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Jade Biosciences during the first quarter worth about $2,164,000. Janus Henderson Group PLC purchased a new position in shares of Jade Biosciences during the first quarter worth about $43,557,000. Quantinno Capital Management LP grew its holdings in shares of Jade Biosciences by 3.6% during the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after purchasing an additional 1,059 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock worth $1,897,000 after purchasing an additional 65,438 shares in the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small?molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.